The Board of Directors at AbbVie has unanimously elected Robert Michael, the company’s current CEO, to assume the additional position of Chairman, effective July 1, 2025. He will succeed Richard Gonzalez, who will retire from the Board of Directors, effective July 1, 2025, and who has served as Chairman since the formation of AbbVie in 2013, following its separation from Abbott. He had previously served as CEO until his retirement from that role in 2024.  

Prior to being named CEO in 2024, Mr. Michael was President and Chief Operating Officer of AbbVie and has been a long-standing member of the company’s Executive Leadership Team. In the role of President and Chief Operating Officer, Mr. Michael was responsible for global commercial operations, finance, corporate human resources, global operations, business development and corporate strategy for the company. He was previously appointed Vice Chairman and President in 2022, Vice Chairman, Finance and Commercial Operations in 2021, and Chief Financial Officer in 2018. Mr. Michael has more than 32 years of experience, including leadership roles across multiple businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care and nutrition. He began his career with Abbott as a member of the financial development program. 

Source: AbbVie